TOP > 外国特許検索 > NON-HUMAN TRANSGENIC MAMMALIAN ANIMAL EXPRESSING HUMAN EGFR SPECIFICALLY IN LUNGS

NON-HUMAN TRANSGENIC MAMMALIAN ANIMAL EXPRESSING HUMAN EGFR SPECIFICALLY IN LUNGS NEW 新技術説明会

外国特許コード F170009019
整理番号 (S2015-1988-N55)
掲載日 2017年3月29日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP073053
国際公開番号 WO 2017026383
国際出願日 平成28年8月5日(2016.8.5)
国際公開日 平成29年2月16日(2017.2.16)
優先権データ
  • 特願2015-158369 (2015.8.10) JP
発明の名称 (英語) NON-HUMAN TRANSGENIC MAMMALIAN ANIMAL EXPRESSING HUMAN EGFR SPECIFICALLY IN LUNGS NEW 新技術説明会
発明の概要(英語) [Problem] To provide transgenic mice in which h-EGFR is expressed specifically in the lungs, and which spontaneously develop lung cancer. [Solution] A non-human transgenic mammalian animal (specifically, a transgenic mouse) in which a human [L858R] epidermal growth factor receptor ([L858R]-h-EGFR) gene, which includes an entire genetic region of 28 exons and 27 introns, is inserted downstream of the expression promoter region thereof. When doing so, it is preferable that the expression promoter region includes a tetracycline response element (TRE), and that the non-human transgenic mammal has a reverse tetracycline-controlled transactivator (rtTA) gene inserted downstream of the expression promoter of the lung-specific expression gene in the mammal.
特許請求の範囲(英語) [claim1]
1. On downstream side of the promoter territory for revelation, 28 Exxon and the person who includes all the gene territories of in tron 27 [L858R] the epithelium growth factor receptor ([L858R] - h-EGFR) the non human mammalian the gene is installed [toransujienitsuku] animal.
[claim2]
2. On downstream side of the promoter territory for revelation, 28 Exxon and the person who includes all the gene territories of in tron 27 [L858R+T790M] the epithelium growth factor receptor ([L858R+T790M] - h-EGFR) the non human mammalian the gene is installed [toransujienitsuku] animal.
[claim3]
3. In the claim 1 which at least is one which is selected from the group where the aforementioned non human Mammalia, the mouse, rut/rat, the cover, the sheep, are good, consist of the cow, the dog, the cat and the monkey or 2 the [toransujienitsuku] animal of statement.
[claim4]
4. As for the promoter territory for the aforementioned revelation, as tetracycline response element (TRE) it includes, as for particular non human [toransujienitsuku] Mammalia, furthermore on downstream side of the revelation promoter of the lung unique revelation gene in particular Mammalia, reverse tetracycline adjustment characteristic trance activated factor (rtTA) either of the claim 1-3 where the gene is installed in one the [toransujienitsuku] animal of statement.
[claim5]
5. As for the aforementioned lung unique revelation gene, the [kurara] cell secretion protein (CCSP), [sahuakutanto] protein A (SPA), [sahuakutanto] protein B (SPB), [sahuakutanto] protein C (SPC) either of the claim 1-4 which at least is one which is selected from the group which consists of in one the [toransujienitsuku] animal of statement.
[claim6]
6. The aforementioned non human Mammalia are the mouse, with the dosage of [dokishisaikurin], the lung cancer in the claim 4 which emerges or 5 the [toransujienitsuku] animal of statement.
[claim7]
7. As for system of the above-mentioned mouse, in the claim 6 which is C57BL/6J the [toransujienitsuku] animal of statement.
[claim8]
8. The decoration process where it installs the cassette for selection in Ex21 of the h-EGFR gene in BAC which includes the h-EGFR gene where the (1)28 contains all the gene territories of in tron of Exxon and 27, [L858R] it arranges on the both ends of mutation the gene recombination process for selection which obtains the gene introduction h-EGFR gene for selection, (2) the genome arrangement of the front and back of Ex21 of the gene introduction h-EGFR gene for the aforementioned selection as a homology arrangement, produces EGFR transfer construction, (3) the cassette for selection the description above Ex21 [L858R] of EGFR transfer construction the substitution process which is substituted with mutation [ripeahuragumento], (4) [L858R] - h-EGFR 5In the claim 6 which features that the process where ' the gene manufacturing process for receptor revelation which is made the gene for receptor revelation which connects the promoter territory for the aforementioned revelation on side, (5) it refines with the gene for the aforementioned receptor revelation, and the gene for m-SSCPrtTA RecBAC revelation micro injection does in the mouse embryo, obtains [toransujienitsukumausu] is had or 7 production method of the [toransujienitsuku] animal of statement.
[claim9]
9. The decoration process where it installs the cassette for selection in Ex21 of the h-EGFR gene in BAC which includes the h-EGFR gene where the (1)28 contains all the gene territories of in tron of Exxon and 27, [L858R] it arranges on the both ends of mutation the gene recombination process for selection which obtains the gene introduction h-EGFR gene for selection, (2) the genome arrangement of the front and back of Ex21 of the gene introduction h-EGFR gene for the aforementioned selection as a homology arrangement, produces EGFR transfer construction, (3) the cassette for selection the description above Ex21 [L858R] of EGFR transfer construction the substitution process which is substituted with mutation [ripeahuragumento], (4) [L858R] - h-EGFR 5' The gene manufacturing process for receptor revelation which is made the gene for receptor revelation which connects the promoter territory for the aforementioned revelation on side, (4-1) it was obtained with gene manufacturing process for the aforementioned receptor revelation, the 2nd decoration process where [L858R] - it installs the cassette for selection in Ex20 of h-EGFR, [T790M] it arranges on the both ends of mutation gene introduction for selection [L858R] - the gene recombination process obtains the h-EGFR gene for 2nd selection which, (4-2) gene introduction for the aforementioned 2nd selection [L858R] - the genome arrangement of the front and back of Ex20 of the h-EGFR gene as a homology arrangement, produces EGFR transfer construction, (4-3) In the claim 6 which features that the process where the cassette for selection the description above Ex20 [T790M] of EGFR transfer construction by the fact that it substitutes with mutation [ripeahuragumento], the gene manufacturing process is made the gene has the promoter territory for the aforementioned revelation 5 ' on the side of EGFR for 2nd receptor revelation which for 2nd receptor revelation which, (5) it refines with the gene for the aforementioned 2nd receptor revelation, and the gene for m-SSCPrtTA RecBAC revelation micro injection does in the mouse embryo, obtains [toransujienitsukumausu] is had or 7 production method of the [toransujienitsuku] animal of statement.
[claim10]
10. As for the number of bases of the primer of pair for the PCR reaction which is used the occasion where the gene introduction h-EGFR gene for the aforementioned selection is produced, in the claim 8 which features that they are 50 base -60 bases or 9 production method of [toransujienitsukumausu] of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • MIE UNIVERSITY
  • 発明者(英語)
  • GABAZZA ESTEBAN CESAR
  • GABAZZA CORINA
国際特許分類(IPC)
指定国 (WO201726383)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
さらに詳しい情報をご要望の方は、下記「問合せ先」までお問い合わせください。未公開情報等の交換をおこなう場合は秘密保持契約を締結しての面談等にて対応しております。

PAGE TOP

close
close
close
close
close
close